Latest Mucinoses Stories
Systemic scleroderma has slowed Tracy Zinn but it has not stopped her from working.
Going Social to Spread the Word in 2011 DANVERS, Mass., May 31, 2011 /PRNewswire-USNewswire/ -- June is Scleroderma Awareness Month, and you can become an advocate for the Scleroderma Foundation by raising awareness and teaching others about this chronic, connective tissue disease.
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial.
Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud's phenomenon in patients with limited cutaneous systemic sclerosis (lcSSc), also known as scleroderma.
New research from Georgetown University Medical Center (GUMC) suggests that up to 40 percent of scleroderma patients will not be correctly diagnosed with the disorder using a new automated commercial screening test.
DANVERS, Mass., Sept. 30 /PRNewswire-USNewswire/ -- The Scleroderma Foundation applauds the U.S. House of Representatives today for the passage of the Scleroderma Research and Awareness Act (H.R. 2408), introduced last March by Rep. Lois Capps (D-CA) and Rep. Vern Ehlers (R-MI).
SOUTH SAN FRANCISCO, Calif., Aug. 25 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRIÂ® for the company's epoprostenol for injection therapy.
Golf Tournament to Raise Funds for the Scleroderma Foundation, Southern California Chapter LOS ANGELES, Aug. 18 /PRNewswire-USNewswire/ -- The 2nd Annual "Fight for Lexi" Charity Golf Tournament takes place on Monday, August 23, 2010 at the Dove Canyon County Club.
DALLAS, June 21 /PRNewswire-USNewswire/ -- The Scleroderma Foundation's Texas Bluebonnet Chapter is pleased to announce its third annual Dallas/Fort Worth "Stepping Out to Cure Scleroderma" walk-a-thon to benefit the programs and services of the chapter and to help fund medical research aimed at finding the cause and cure for scleroderma, a little-known but devastating autoimmune disease.
There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin").